SEARCH

SEARCH BY CITATION

References

  • 1
    Torrance G, Blaker D, Detsky A, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Pharmacoeconomics 1996;9: 53559.
  • 2
    Jacobs J, Bachynsky J, Baladi J. A comparative review of pharmacoecomomic guidelines. Pharmacoeconomics 1995;8: 1829.
  • 3
    Jameson EJ, Wehr E. Drafting national health reform legislation to protect the health interests of children. Stanford Law Policy Rev 1993;Fall: 15276.
  • 4
    Starfield B, Newacheck P. Children's health status, health risks and use of health services. In: SchlesingerMJ, EisenbergL, eds., Children in a Changing Health System: Assessments and Proposals for Reform. Baltimore: Johns Hopkins University Press, 1990.
  • 5
    Perrin JM. Introduction. In: HobbsN, PerrinMJ, eds., Issues in the Care of Children with Chronic Illness. San Francisco: Jossey-Bass, 1985.
  • 6
    Bronfenbrenner U, Moen P, Garbarino J. Families and communities. In: ParkeHR, ed., Review of Child Development Research. Chicago: University of Chicago Press, 1984.
  • 7
    Halfon N, Newacheck PW. Characterizing the social impact of asthma in children. In: WeissKB, BuistAS, SullivanSD, eds., Asthma's Impact on Society, the Social and Economic Burden. New York: Dekker, 2000.
  • 8
    Ungar W, Santos M. The Pediatric Economic Database Evaluation (PEDE) Project [Internet]. Technology Report No. 26. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2002 Available from: http://www.ccohta.ca/entry_e.html.
  • 9
    Ganiats TG, Wong AF. Evaluation of cost-effectiveness research: a survey of recent publications. Fam Med 1991;23: 45762.
  • 10
    Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomized control trials. Med Care 1992;30: 23143.
  • 11
    Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature: are the methods being used correctly? Ann Intern Med 1992;116: 23844.
  • 12
    Lee JT, Sanchez LA. Interpretation of “cost-effective” and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm 1991;48: 26227.
  • 13
    Gerard K. Cost-utility in practice: a policy maker's guide to the state of the art. Health Policy 1992;21: 24979.
  • 14
    Sacristan JA, Soto J, Galende I. Evaluation of pharmacoeconomic studies: utilization of a checklist. Ann Pharmacother 1993;27: 112633.
  • 15
    Bradley CA, Iskedjian M, Lanctot KL, et al. Quality assessment of economic evaluations in selected pharmacy, medical, and health economics journals. Ann Pharmacother 1995;29: 6819.
  • 16
    Blackmore CC, Magid DJ. Methodologic evaluation of the radiology cost-effectiveness literature. Radiology 1997;203: 8791.
  • 17
    Iskedjian M, Trakas K, Bradley CA, et al. Quality assessment of economic evaluations published in PharmacoEconomics: the first four years (1992 to 1995). Pharmacoeconomics 1997;12: 68594.
  • 18
    Trakas K, Addis A, Kruk D, et al. Quality assessment of pharmacoeconomic abstracts of original research articles in selected journals. Ann Pharmacother 1997;31: 4238.
  • 19
    Canadian Coordinating Office for Health Technology Assessment. Guidelines for the Economic Evaluation of Pharmaceuticals: Canada [Inter-net] (2nd ed.). Ottawa: The Office, 1997. Avail-able from: http://www.ccohta.ca/entry_e.html.
  • 20
    Drummond MF, O'Brien B, Stoddart GL, Torrance GW, eds. Methods for the Economic Evaluation of Health Care Programs (2nd ed.). Toronto: Oxford University Press, 1997.
  • 21
    Evidence-Based Medicine Working Group. Finding and Using an Article about an Economic Analysis [Internet]. Edmonton: Evidence-Based Medicine Working Group, University of Alberta, 2000. Available from: http://www.med.ualberta.ca/ebm/econ.htm.
  • 22
    Gerard K, Seymour J, Smoker I. A tool to improve quality of reporting published economic analyses. Int  J  Technol  Assess  Health  Care 2000;16: 10010.
  • 23
    Ontario Guidelines for Economic Analysis of Pharmaceutical Products [Internet]. Cat. No. 2227446. Toronto: Ontario Ministry of Health and Long-Term Care, 1994. Available from: http://www.gov.on.ca/health/english/pub/drugs/drugpro/economic.pdf.
  • 24
    Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276: 133941.
  • 25
    Elixhauser A, Halpern M, Schmier J, Luce BL. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care 1998;36(5 Suppl):MS1MS147.
  • 26
    Pritchard C. Trends in Economic Evaluation. OHE Briefing Number 36. London: Office of Health Economics, Health Economic Evaluations Database, 1998 Apr.
  • 27
    Drummond M, Brandt A, Luce B, Rovira J. Standardizing methodologies for economic evaluation in health care. Int J Technol Assess Health Care 1993;9: 2636.
  • 28
    Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276: 12538.
  • 29
    Australia Commonwealth Department of Health Housing and Community Services. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Commonwealth Department, 1992.